Ashley v. Abbott Laboratories

789 F. Supp. 552, 1992 U.S. Dist. LEXIS 5560
CourtDistrict Court, E.D. New York
DecidedApril 13, 1992
DocketNos. CV 91-3748, CV 91-4986
StatusPublished
Cited by4 cases

This text of 789 F. Supp. 552 (Ashley v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Ashley v. Abbott Laboratories, 789 F. Supp. 552, 1992 U.S. Dist. LEXIS 5560 (E.D.N.Y. 1992).

Opinion

MEMORANDUM AND ORDER

Personal Jurisdiction

WEINSTEIN, District Judge:

[557]*557TABLE OF CONTENTS

I. INTRODUCTION.557

II. FACTS.558

A. Background.558

B. Present Actions.559

C. Motions.559

III. NEW YORK SUBSTANTIVE LAW AND RULES AFFECTING SUBSTANTIVE RIGHTS. cn C5 o

A. History of New York Products Liability Law and Mass Tort Law Generally. B. New York DES Law. C. Constitutionality of New York DES Law en o* cj* CTi CTi Ü1COO

IV. CHOICE OF LAW.566

A. Erie Doctrine.566

B. New York Choice-of-Law Rules in Mass DES Torts.566

C. Constitutionality of New York Choice-of-Law Rules in Mass DES Torts...568

Y. PERSONAL JURISDICTION. cn os to
A. New York Jurisdictional Statutes. cn c* cr>

1. C.P.L.R. § 301. cn as *©

2. C.P.L.R. § 302. en cí co

B. Constitutionality of New York Statutes en ~q co

1. Current Due Process Doctrine and Problems Raised by Its Application to Mass Torts . en -a co

2. Case Law in Non-Mass Torts. en -q ~q

a. Pennoyer and Its Problems. en -q

b. Pennoyer to International Shoe: The Emergency of Fairness Inquiry. en oo o

c. International Shoe: Sovereignty, Fairness and Nexus Requirements . 3. Sovereignty and Fairness in Mass Torts ... 4. Due Process Standard for Mass DES Torts en en en oooooo -q ^ to

VI. APPLICATION OF LAW TO FACTS.589
A. Boehringer.589
1. Failure to State a Claim.589
2. Personal Jurisdiction.591
B. Boyle.592

1. C.P.L.R. § 302(a)(3)(ii).592

2. Due Process.593
VII. CONCLUSION.594
I. INTRODUCTION

This diversity case presents a classic illustration of why traditional limits on personal jurisdiction must be modified for mass torts. The torts alleged here involve numerous claims of injury from exposure in útero to diethylstilbestrol (DES). DES was developed and tested in laboratories throughout the country and the world. Permission to use it was sought and obtained from the federal Food and Drug Administration by pharmaceutical companies scattered across the nation. Some companies conducted national advertising and a national corps of salespersons hawked the drug in doctors’ offices in every part of the country. Discussions among medical specialists and word-of-mouth information traded among doctors and patients led to national acceptance of the drug as useful for the prevention of miscarriages. Even companies producing [558]*558exclusively for local markets relied on the nationally developed understanding and consensus about DES and used knowledge and chemicals from all parts of the United States and the world. Thousands of persons in hamlets and cities across the country are now claiming to have been adversely affected by exposure to the drug. In short, the technology, marketing, sociology, and possible ill effects of DES knew no state boundaries. The national nature of the resulting toxic tort litigation must be reflected in the law’s treatment of jurisdictional issues.

Motions to dismiss for lack of jurisdiction raise the following questions: Do the complaints against the moving defendants state a claim under New York’s substantive laws? Are those laws constitutional? Are New York’s substantive laws applicable under New York’s choice-of-law rules? Are those choice-of-law rules constitutional? Do New York’s jurisdictional statutes provide for jurisdiction over a successor corporation licensed to do business in New York for causes of action relating to the activities of its predecessor corporation, which never sold DES in New York and was never present in New York? Does New York’s long arm statute provide for jurisdiction over a manufacturing corporation which never sold DES in the New York market and was never present in New York? Are New York’s jurisdictional statutes constitutional? In light of the specific characteristics and history of the moving defendants, and of all the parties and the suit, would requiring the defendants to litigate in New York be fair so that jurisdiction is not barred by the Constitution and should not be declined under a prudential theory akin to forum non conveniens? All must be answered “yes.”

II. FACTS
A. Background

DES, a synthetic estrogen, was developed in the late 1930s. It was thought to be useful in treating symptoms of certain cancers and menopause, among other things. In 1941, twelve companies formed a committee to oversee submissions in support of a joint New Drug Application for DES to the Food and Drug Administration. On the basis of these submissions, the FDA approved DES for certain uses, not including the prevention of miscarriages.

Researchers were simultaneously discovering that miscarriages were often accompanied by low levels of natural estrogen. In theory, the administration of natural or synthetic estrogen would improve a woman’s ability to carry the pregnancy to term. In 1947 and 1948 several of the twelve DES manufacturers sought and were granted permission by the FDA to market DES to prevent miscarriage and fetal death. By 1952 the FDA considered DES proven safe. Hundreds of additional manufacturers then entered the market. Millions of pregnant women ingested DES during the 1950s and 1960s.

In 1971, doctors in Boston concluded that DES was a teratogen responsible for the appearance of adenocarcinoma, a rare form of vaginal cancer, in eight young women who had been exposed to DES in the womb. The FDA soon thereafter disapproved the continued marketing of DES for pregnancy use. There is some evidence that doctors nonetheless continued to prescribe DES through the early'1970s.

Women exposed to DES in útero may develop adenosis, a pre-cancerous cell change which can be treated by cauterization or surgery. DES is said to cause a variety of other more serious disorders, including miscarriage, uterine deformities, ectopic pregnancy, and breast cancer. Male fetuses exposed to DES may be at risk of developing undescended testicles, sterility, and deformities. As persons exposed to DES in útero age, other medical problems may be linked to DES. There is also evidence that DES daughters pass on defects to their own female children. Whether permanent inheritable genetic damage will be spread more widely in future generations is uncertain.

DES was sold as a generic drug. It was produced in tablets of various dosages according to the same formula by all manufacturers and marketed nationally under a generic description. Pharmacists filled [559]*559prescriptions by using DES manufactured by different companies interchangeably. Each of the many manufacturers produced and sold DES for different periods between 1949 and 1971. Some of the companies that made and sold DES no longer exist.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Waste Management, Inc. v. Admiral Ins. Co.
649 A.2d 379 (Supreme Court of New Jersey, 1994)
Waste Management, Inc. v. Admiral Insurance
649 A.2d 379 (Supreme Court of New Jersey, 1994)
Burroughs v. Northern Telecom, Inc.
142 F.R.D. 584 (E.D. New York, 1992)
In Re DES Cases
789 F. Supp. 552 (E.D. New York, 1992)

Cite This Page — Counsel Stack

Bluebook (online)
789 F. Supp. 552, 1992 U.S. Dist. LEXIS 5560, Counsel Stack Legal Research, https://law.counselstack.com/opinion/ashley-v-abbott-laboratories-nyed-1992.